Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genetic Technologies ( (AU:GTG) ) has provided an announcement.
Genetic Technologies Limited remains under external administration as Deed Administrators progress implementation of a Deed of Company Arrangement and a proposed recapitalisation, following creditors’ approval in February 2025. The company is effectively non-trading after completing the sale of its geneType business to Rhythm Biosciences for $625,000, including transfer of key intellectual property, contracts and certain employees.
During the March 2025 quarter, Genetic Technologies received $510,000 in proceeds from asset disposals, ending the period with just $0.27 million in cash and cash equivalents and overall net cash outflows of $0.73 million. With customer receipts sharply lower and all inflows characterised as residual rather than operational, the company’s future now hinges on successful recapitalisation under the DOCA and the strategic repositioning that follows the divestment of its principal operating business.
The most recent analyst rating on (AU:GTG) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Genetic Technologies stock, see the AU:GTG Stock Forecast page.
More about Genetic Technologies
Genetic Technologies Limited is an Australian biotechnology company formerly focused on its geneType business, which developed genetic risk assessment tests and related intellectual property. The company operated in the genomics and diagnostics space, serving healthcare and research markets before entering voluntary administration and selling its core geneType assets.
Technical Sentiment Signal: Sell
Current Market Cap: A$5.67M
Find detailed analytics on GTG stock on TipRanks’ Stock Analysis page.